Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immunome Inc
(NQ:
IMNM
)
17.18
-0.20 (-1.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
852,764
Open
17.34
Bid (Size)
17.18 (1)
Ask (Size)
17.51 (1)
Prev. Close
17.38
Today's Range
17.15 - 17.97
52wk Range
4.440 - 30.96
Shares Outstanding
59,694,243
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
April 05, 2024
From
Immunome, Inc.
Via
Business Wire
IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023
March 28, 2024
IMNM stock results show that Immunome beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
+56.04%
+56.04%
1 Month
-28.65%
-28.65%
3 Month
+27.45%
+27.45%
6 Month
+109.00%
+109.00%
1 Year
+209.55%
+209.55%
More News
Read More
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
March 28, 2024
From
Immunome, Inc.
Via
Business Wire
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday?
March 28, 2024
Via
Benzinga
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
March 26, 2024
From
Immunome, Inc.
Via
Business Wire
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
March 26, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
March 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Immunome to Participate in the Leerink Partners Global Biopharma Conference
March 07, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
March 01, 2024
From
Immunome, Inc.
Via
Business Wire
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue?
February 28, 2024
Via
Benzinga
How I Swing Trade Via Strength With Recent Examples
February 25, 2024
Via
Talk Markets
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From
Immunome, Inc.
Via
Business Wire
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
February 20, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 16, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Pricing of Public Offering of Common Stock
February 13, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Proposed Public Offering of Common Stock
February 13, 2024
From
Immunome, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 06, 2024
Via
Benzinga
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
February 06, 2024
From
Ayala Pharmaceuticals
Via
GlobeNewswire
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 05, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome - Oncology Is Hot
January 10, 2024
Via
Talk Markets
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
January 08, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Phil Roberts as Chief Technical Officer
January 04, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Immunome, Inc.
Via
Business Wire
Immunome Appoints Carol A. Schafer to Board of Directors
January 02, 2024
From
Immunome, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.